AltMountain

Saturn V Capital Management LP

Austin, TX · CRD 316649
Hedge fund manager

Saturn V Capital Management LP is an SEC-registered investment adviser based in Austin, TX that reports managing 3 hedge funds on Form ADV. It reports $793.2 million in regulatory assets under management. Its private funds, of all types, hold $793.2 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +28.9% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +117.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$793.2 millionForm ADV Item 5.F
Gross assets of private funds
$793.2 millionAll private fund types, Form ADV
Hedge funds managed
33 private funds in total
Employees
6Form ADV Item 5.A
Registration
SEC-registered adviserCRD 316649
Latest Form ADV
08/04/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+28.9%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+117.5%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$697.5 million23 positions, 2026-06-30
$73$145$217Q3 2024Q1 2025Q3 2025Q1 202613F est. $217S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+18.2%+14.8%
Q1 2026+9.1%-4.6%
Q4 2025+29.7%+2.4%
Q3 2025+61.4%+7.8%
Q2 2025+10.7%+10.4%
Q1 2025-21.2%-4.5%
Q4 2024-15.8%+2.1%
Q3 2024+9.7%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 24 share positions ($683,127,656) reported by Saturn V Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Amylyx Pharmaceuticals Inc19.05%
  • Abivax SA7.67%
  • Immix Biopharma Inc7.10%
  • Pharvaris N V6.47%
  • Vaxcyte Inc6.43%
  • Celcuity Inc5.98%
  • Disc Medicine Inc5.87%
  • Candel Therapeutics Inc5.31%
  • Jazz Pharmaceuticals PLC5.10%
  • Monopar Therapeutics Inc3.64%
StockValue% of 13F portfolioSharesShares vs prior quarter
Amylyx Pharmaceuticals Inc$130,116,46019.05%4,471,356-3.30%
Abivax SA$52,412,5737.67%529,313+2.01%
Immix Biopharma Inc$48,498,9027.10%4,661,115+0.06%
Pharvaris N V$44,216,2846.47%1,393,956+6.08%
Vaxcyte Inc$43,941,4806.43%772,258-9.46%
Celcuity Inc$40,861,1135.98%513,847+38.76%
Disc Medicine Inc$40,104,7895.87%612,661+16.76%
Candel Therapeutics Inc$36,291,5915.31%3,476,206+5.22%
Jazz Pharmaceuticals PLC$34,806,7175.10%150,340-6.59%
Monopar Therapeutics Inc$24,884,9243.64%312,350+0.12%
Vir Biotechnology Inc$22,811,9183.34%2,040,422+164.77%
Trevi Therapeutics Inc$22,537,9043.30%1,573,876+49.60%
X4 Pharmaceuticals Inc$21,362,6823.13%7,366,442+5.64%
Alumis Inc$21,104,4433.09%2,855,811-2.05%
Sagimet Biosciences Inc$19,787,7922.90%2,002,813+35.33%
Dyne Therapeutics Inc$13,486,8891.97%837,175-20.83%
Alto Neuroscience Inc$13,227,3231.94%518,109+183.38%
Ultragenyx Pharmaceutical In$11,404,3281.67%758,771New
Zura Bio LTD$8,455,0091.24%2,032,454-3.27%
Inhibikase Therapeutics Inc$7,950,9101.16%3,869,056Unchanged
Oculis Holding AG$7,915,1271.16%847,444+23.74%
Erasca Inc$7,539,7701.10%514,309New
Latigo Biotherapeutics Inc$5,015,9280.73%300,355New
Satellos Bioscience Inc$4,392,8000.64%516,800+47.66%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 3 new positions, 2 sold out, 14 increased, 6 reduced and 1 unchanged.

Number of positions (a count, not dollars)

  • New positions3
  • Increased14
  • Unchanged1
  • Reduced6
  • Sold out2

New positions

StockValueShares
Ultragenyx Pharmaceutical In$11,404,328758,771
Erasca Inc$7,539,770514,309
Latigo Biotherapeutics Inc$5,015,928300,355

Sold out

StockValue at Jun 30, 2026Shares held then
Invivyd Inc$7,321,4328,392,288
Ovid Therapeutics Inc$1,783,631663,060

Largest increases

StockChange in sharesChangeValue nowShares now
Vir Biotechnology Inc+1,269,779+164.77%$22,811,9182,040,422
Celcuity Inc+143,529+38.76%$40,861,113513,847
Alto Neuroscience Inc+335,280+183.38%$13,227,323518,109
Trevi Therapeutics Inc+521,833+49.60%$22,537,9041,573,876
Disc Medicine Inc+87,931+16.76%$40,104,789612,661
Sagimet Biosciences Inc+522,895+35.33%$19,787,7922,002,813
Pharvaris N V+79,834+6.08%$44,216,2841,393,956
Candel Therapeutics Inc+172,520+5.22%$36,291,5913,476,206
Oculis Holding AG+162,564+23.74%$7,915,127847,444
Satellos Bioscience Inc+166,800+47.66%$4,392,800516,800
X4 Pharmaceuticals Inc+393,099+5.64%$21,362,6827,366,442
Abivax SA+10,448+2.01%$52,412,573529,313
Monopar Therapeutics Inc+374+0.12%$24,884,924312,350
Immix Biopharma Inc+2,686+0.06%$48,498,9024,661,115

Largest reductions

StockChange in sharesChangeValue nowShares now
Vaxcyte Inc-80,656-9.46%$43,941,480772,258
Amylyx Pharmaceuticals Inc-152,745-3.30%$130,116,4604,471,356
Dyne Therapeutics Inc-220,318-20.83%$13,486,889837,175
Jazz Pharmaceuticals PLC-10,598-6.59%$34,806,717150,340
Alumis Inc-59,632-2.05%$21,104,4432,855,811
Zura Bio LTD-68,665-3.27%$8,455,0092,032,454

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Monopar Therapeutics13G amendment4.7%313,384Aug 12, 2026SEC.gov ↗
Immix Biopharma, Inc.13G6.97%3,693,585Feb 17, 2026SEC.gov ↗
X4 Pharmaceuticals, Inc.13G7.36%6,433,481Feb 17, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Feb 17, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (1)

Fund
Gross assets
Minimum
Owners
Adviser
Saturn V Capital LP
Delaware, United StatesHedge fund
Gross assets$223M
Minimum$1.0M
Owners32
AdviserSaturn V Capital Management LP

As reported in the adviser's Form ADV filed Apr 17, 2024. Funds also listed from Form D are shown above.

Fund vehicles: feeder funds and single-deal vehicles (1)

Fund
Gross assets
Minimum
Owners
Adviser
Blackwell Partners LLC - Series a
Delaware, United StatesHedge fund
Gross assets$178M
MinimumNone set
Owners1
AdviserSaturn V Capital Management LP

Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌‌⁠